変形性膝関節症に対するヒアルロン酸ナトリウム架橋体製剤（サイビスクディスポ®）の効果

DOI Web Site

書誌事項

タイトル別名
  • The Efficacy of Hylan G-F 20 (Synvisc®) with Osteoarthritis of the Knee
  • 変形性膝関節症に対するヒアルロン酸ナトリウム架橋体製剤(サイビスクディスポ)の効果
  • ヘンケイセイ シツカンセツショウ ニ タイスル ヒアルロンサン ナトリウム カケハシ タイセイザイ(サイビスクディスポ)ノ コウカ

この論文をさがす

抄録

Objective: Synvisc® is a cross-linked hyaluronan preparation with higher viscosity than existing hyaluronan preparations and with more powerful and longer-lasting analgesic effects. The objective of this study was to evaluate the efficacy and safety of Synvisc® in patients persistently experiencing pain after treatment with an existing hyaluronan preparation (Artz®).<br>Methods: Subjects included 45 patients (70 knee joints) with osteoarthritis of the knee with persistent pain after treatment with Artz®. Synvisc® was administered three times at weekly intervals. Visual analog scale (VAS) was recorded before treatment and after 1 week, 2 weeks, 3 months and 6 months, respectively. Japanese Orthopedic Association (JOA) score was recorded before treatment and after 6 months. These scores were then analyzed accordingly.<br>Results: JOA scores improved significantly (from 76.9 to 81.9) after 6 months compared to before treatment. VAS scores during movement improved significantly after 1 week, and continued to improve up to 6 months (from 51.6 to 36.6). However, no significant effect was seen in the severe osteoarthritis group (Kellgren-Lawrence Grade III or IV; 23 patients) or in the group given Artz® for ≥ 1 year (31 patients). One of the 45 Synvisc® patients experienced a local adverse event.<br>Conclusions: Synvisc® is a useful medication in patients who do not respond adequately to Artz®. Efficacy was low in cases with severe deformation or persistent osteoarthritis, potentially representing a limitation of hyaluronan preparations in general. More local adverse events were seen with Synvisc® than with Artz®. Synvisc® should therefore be used with caution, taking account of the potential risks and benefits.

収録刊行物

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ